Gennex Laboratories

Gennex Laboratories Equity

The The Equity of Gennex Laboratories (531739.BO) as of Nov 9, 2026 is 2.23 B INR. In the previous year, The Equity was 1.87 B INR — a change of 19.19% (higher).

Equity

2.23 BINR

YoY

19.19%

Last updated:

In 2026, Gennex Laboratories's equity was 2.23 B INR, a 19.19% increase from the 1.87 B INR equity in the previous year.

The Gennex Laboratories Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
338.15 M INR
Jan 1, 2020
358.54 M INR
Jan 1, 2021
397.10 M INR
Jan 1, 2022
438.15 M INR
Jan 1, 2023
803.50 M INR
Jan 1, 2024
1.70 B INR
Jan 1, 2025
1.87 B INR
Jan 1, 2026
2.23 B INR
The Gennex Laboratories Equity history
YEAREquityYoY
2.23 BINR+19.19%
1.87 BINR+9.57%
1.70 BINR+112.05%
803.50 MINR+83.38%
438.15 MINR+10.34%
397.10 MINR+10.75%
358.54 MINR+6.03%
338.15 MINR+6.45%
317.68 MINR+2.69%
309.37 MINR+9.56%
282.37 MINR+10.62%
255.26 MINR+0.55%
253.87 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Gennex Laboratories Stock analysis

What does Gennex Laboratories do? Gennex Laboratories Ltd manufactures bulk drugs and intermediates, including active pharmaceutical ingredients like Guaifenesin USP/BP/EP/IP for expectorants, Methocarbamol USP for muscle relaxants, Phenazopyridine Hcl USP for urinary tract analgesics, Fluconazole EP/USP for anti-fungal products, Mephenesin IP/BP for muscle relaxants, Chlorphenesin IP/BP for anti-fungal, and Melitracen Hcl as an antidepressant. The company operates through the Pharmaceutical Products (Bulk Drugs) segment, serving domestic and international markets from its Indian manufacturing facilities. Its product portfolio spans expectorants, muscle relaxants, analgesics, and anti-fungals, with specific ingredients targeting respiratory, musculoskeletal, urinary, and fungal conditions. Gennex Laboratories Ltd targets pharmaceutical companies and healthcare providers globally, supplying bulk drugs and intermediates for formulation into final medicines. The firm’s manufacturing facilities in India produce active pharmaceutical ingredients under strict quality standards, including USP, BP, EP, and IP specifications. Its products serve key therapeutic segments such as respiratory care, pain management, and antifungal treatments, directly supporting drug manufacturers in developing finished pharmaceutical products for consumer markets. The company’s revenue streams derive from the sale of bulk drug ingredients to pharmaceutical manufacturers, who integrate them into their own branded products. Gennex’s portfolio includes established ingredients like Guaifenesin and Fluconazole, which are widely used in global pharmaceutical supply chains. By focusing on high-demand therapeutic areas, Gennex ensures consistent demand for its bulk drug offerings across domestic and international pharmaceutical markets. Gennex Laboratories is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Gennex Laboratories's Equity

Gennex Laboratories's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Gennex Laboratories's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Gennex Laboratories's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Gennex Laboratories's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Gennex Laboratories’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Gennex Laboratories stock

The Equity of Gennex Laboratories is 2.23 B INR in 2026.

The Equity of Gennex Laboratories changed from 1.87 B INR to 2.23 B INR, representing a 19.19% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Gennex Laboratories since 2006 – with annual values, charts, and detailed analysis.

The Equity's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Gennex Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Gennex Laboratories

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Gennex Laboratories